New Light-Initiated Drug Delivery Studied
Posted on: Tuesday, 7 August 2007, 15:10 CDT
Northern Irish scientists, in a move toward delivering medication directly to diseased tissue, have developed a light-controlled dosing system.
Colin McCoy and colleagues at Queen's University Belfast said their new molecular-scale dosing system is a new paradigm for price control of drug dosing using light that minimizes side effects and damage to healthy parts of the body.
The technique consists of medications combined with certain chemical compounds that respond to light in ways that release precisely controlled amounts of the drug. Drug release begins when light falls on the compounds, and lasts only as long as the light continues to shine.
The study reports successful laboratory tests of the system in the controlled release of three common medications used to treat pain and inflammation -- aspirin, ibuprofen and ketoprofen.
One potential use cited in the study would be in the treatment of urinary catheter infections. The system might also be applied in other conditions using an implant under the skin for precisely controlled drug dosing, the researchers suggest.
The study is scheduled to appear in the Aug. 15 issue of the Journal of the American Chemical Society.
Source: United Press International
Related Articles
- First Pediatric Patient Treated With Aptocine(TM), a Novel Light-Activated Drug, in Neurofibromatosis Study
- Community Hospital North Deploys ForHealth's Dose Preparation System
- Hythiam to Announce Urschel Double-Blind Placebo-Controlled Study Results on Thursday, November 1st
- An Investigational Study Released at ADA Showed That Initial Combination Therapy With JANUVIA(TM) (Sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients With Type 2 Diabetes
- Light Dimensions Introduces RejuvaWand Non-Invasive Light Enhanced Skincare System for Home Use
- Debiopharm S.A. Presented Results of a Double-Blind Placebo-Controlled Study on First-in-Class Debio-025 in HIV-1-Infected Subjects
- A Preliminary Study on Reduced Dose (33 or 25 G) Gonadotropin- Releasing Hormone Agonist Long Protocol for Multifollicular Ovarian Stimulation in Patients With High Basal Serum Follicle-Stimulating Hormone Levels Undergoing in Vitro Fertilization-Embryo T
- Most newer schizophrenia drugs no better - study
- Most newer schizophrenia drugs no better: study
- A Nested Case-Control Study on Treatment-Related Risk Factors for Early Relapse of Tuberculosis
 |
 |
User Comments (0)
RSS Feeds